A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Clinical trial NCT05039619 · RECRUITING

Trial details

NCT number: NCT05039619
Sponsor: Hoffmann-La Roche
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lupus Nephritis

Start date: 2022-05-12
Primary completion: 2028-06-15
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.